Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

8.020 -0.240 (-2.91%)
Streaming Delayed Price Updated: 3:27 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
News headline image
Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast Raise ↗
Via MarketBeat
News headline image
Nasdaq, S&P 500 Futures Edge Higher, Trump Speech In Focus: Why WMT, META, IBRX, MSFT, EBAY Are On Traders' Radar Today ↗
Data from Stocktwits indicated retail sentiment towards SPY and QQQ cooled to neutral. 
Via Stocktwits
Topics ETFs Economy Government
News headline image
Compass Pathways Announces Pricing of $150 Million Public Offering
From Compass Pathfinder Limited
Via Business Wire
CMPS Stock Climbs 5% In Premarket After FDA Clears PTSD Trial Path ↗
Via Stocktwits
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
CMPS Stock Slumps Premarket As $150M Offering Cuts Into Psychedelic Trial Buzz ↗
The company CMPS is planning to seek FDA guidance on a rolling review and target a New Drug Application submission in the fourth quarter. 
Via Stocktwits
News headline image
Compass Pathways Launches Proposed $150.0 Million Public Offering
From Compass Pathfinder Limited
Via Business Wire
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
News headline image
Why Did Compass Pathways Stock Rocket Higher Today? ↗
Compass Pathways hopes to submit an NDA in Q4 leading up to potential approval. 
Via The Motley Fool
Tuesday's session: gap up and gap down stocks ↗
Via Chartmill
Tuesday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
From Compass Pathfinder Limited
Via Business Wire
News headline image
CMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trial ↗
COMPASS Pathways is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression. 
Via Stocktwits
News headline image
CMPS Stock Jumps 22% Pre-Market As Compass Sets Timeline For New Phase 3 Depression Trial Results ↗
The company is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression. 
Via Stocktwits
News headline image
Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360
From Compass Pathfinder Limited
Via Business Wire
News headline image
Psychedelics Break Out Of The Fringe Under RFK Jr’s 2025 Reset — But Did MNMD Or CMPS Own The Year? ↗
Regulatory thaw, political backing, and late-stage data are propelling psychedelic drugmakers into the biotech spotlight — with Compass Pathways and Mind Medicine leading the charge. 
Via Stocktwits
Topics ETFs
News headline image
Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Participate in Two Investor Conferences in December
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Participate in Stifel 2025 Healthcare Conference
From Compass Pathfinder Limited
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025
From Compass Pathfinder Limited
Via Business Wire
News headline image
Design Therapeutics Appoints Justin Gover to Board of Directors
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Participate in Four Investor Conferences in September
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Participate in Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass (CMPS) Q2 Loss Improves 27% ↗
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.